<SEC-DOCUMENT>0001575872-26-000536.txt : 20260729
<SEC-HEADER>0001575872-26-000536.hdr.sgml : 20260729
<ACCEPTANCE-DATETIME>20260728211722
ACCESSION NUMBER:		0001575872-26-000536
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260728
FILED AS OF DATE:		20260729
DATE AS OF CHANGE:		20260728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DR REDDYS LABORATORIES LTD
		CENTRAL INDEX KEY:			0001135951
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			K7
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15182
		FILM NUMBER:		261213663

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		8-2-337, ROAD NO.3 BANJARA HILLS
		CITY:			HYDERABAD
		PROVINCE COUNTRY:   	K7
		ZIP:			500-034
		BUSINESS PHONE:		91 40 49002900

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		8-2-337, ROAD NO.3 BANJARA HILLS
		CITY:			HYDERABAD
		PROVINCE COUNTRY:   	K7
		ZIP:			500-034
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>rdy0931_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>July 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number 1-15182</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DR. REDDY&rsquo;S LABORATORIES LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>8-2-337, Road No. 3, Banjara Hills</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Hyderabad, Telangana 500 034, India</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>+91-40-49002900</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note:</B> Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note: </B>Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBITS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Exhibits</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="rdy0931_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="rdy0931_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intimation dated July 28, 2026 </FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DR. REDDY&rsquo;S LABORATORIES LIMITED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Registrant)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 28, 2026</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ K Randhir Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K Randhir Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rdy0931_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
    Reddy&rsquo;s Laboratories Ltd.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-2-337,
    Road No. 3, Banjara Hills</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyderabad
    &ndash; 500 034, Telangana, India</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CIN:
    L85195TG1984PLC004507</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:&#160;&#160;&#160;&#160;&#160;+
    91 40 4900 2900</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:&#160;&#160;&#160;&#160;&#160;+
    91 40 4900 2999</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&nbsp;<U>mail@drreddys.com</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Web:
    &nbsp;<U>www.drreddys.com</U></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
28, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
Stock Exchange of India Ltd. (Stock Code: DRREDDY)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BSE
Limited (Stock Code: 500124)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York Stock Exchange Inc. (Stock Code: RDY)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NSE
IFSC Ltd. (Stock Code: DRREDDY)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir/ Madam,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub:
Transcript of the Earnings call conducted on July 22, 2026 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please
find enclosed the transcript of the Earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026. Also please note that
this transcript of the call has been uploaded on our website and are available at the following link.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weblink:
https://www.drreddys.com/cms/sites/default/files/2026-07/DRL_Q1FY27EarningsCall%20Transcript_22July2026.pdf</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is for your information and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanking
you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
faithfully,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
<B>Dr. Reddy&rsquo;s Laboratories Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img02.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K
Randhir Singh</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
Secretary, Compliance Officer &amp; Head-CSR</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><IMG SRC="rdy0931_ex99-1img01.jpg" ALT="">&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Reddy&rsquo;s Laboratories Limited&rsquo;s&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q1FY27
Earnings Call</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
22, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Management:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Mr.
    Erez Israeli: Chief Executive Officer</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Mr.</B></FONT><B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.
    V. <FONT STYLE="font-variant: small-caps">Narasimham: Chief Financial Officer</FONT></FONT></B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M<FONT STYLE="font-variant: small-caps">s</FONT>.
    <FONT STYLE="font-variant: small-caps">Aishwarya Sitharam: Head &ndash; Investor Relations</FONT></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220pt; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I>&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good day, everyone, and welcome
    to the Quarter 1 FY27 earnings call of Dr. Reddy&rsquo;s Laboratories Limited. We appreciate your continued interest in our Company. I&rsquo;m
    Aishwarya Sitharam, Head of Investor Relations at Dr. Reddy&rsquo;s. Joining us today are members of the leadership team, Mr. Erez
    Israeli, our Chief Executive Officer and Mr. M. V. Narasimham (MVN), our Chief Financial Officer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our quarterly financial results have been published
    earlier today and are available on our website for your reference.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will start today&rsquo;s call with MVN providing
    an overview of our financial performance for the quarter. Following that, Erez will share his insights on key business highlights,
    as well as the Company&rsquo;s strategic outlook. We will then open the floor for questions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All commentary and analysis during this call are based
    on our IFRS Consolidated financial statements. Please note that certain non-GAAP financial measures may also be discussed. Reconciliations
    to the corresponding GAAP measures are included in our press release. I would like to remind everyone that the &lsquo;Safe Harbor&rsquo;
    provisions outlined in our press release today apply to all forward-looking statements made during this call.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before we proceed, I would like to call out a few housekeeping
    points. All participants will be in the &lsquo;listen-only&rsquo; mode during the opening remarks. Should you need any technical
    assistance during the call, please use the chat function in your Zoom application. The chat, however, will not be monitored for any
    questions to the management. This session is being recorded, and both the recording as well as the transcript will be made available
    on our website shortly. Please note that this call is the proprietary material of Dr. Reddy&rsquo;s Laboratories Limited and may not be
    rebroadcasted or quoted in any media or public forum, without prior, written consent from the company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With that, let me hand the call over to MVN to present
    the financial highlights for the quarter. Over to you, MVN.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you, Aishwarya. Greetings to everyone on the
    call. It is my pleasure to walk you through our financial performance for the first quarter of FY27.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business reported a revenue decline of 5.6% and
    an EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding
    period last year, as well as a provision of &#8377;240 crores for inventory and other costs associated with the recent semaglutide
    API related challenges. Notably, the underlying base business, excluding lenalidomide, continued to deliver healthy double-digit
    growth across all key geographies, including North America, supported by new product launches and favourable currency movements.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All financial figures in this section are translated
    into US dollars, using a convenience translation rate of &#8377;94.66, the exchange rate prevailing as of June 30, 2026.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated revenues stood at &#8377;8,071
    crores, which is US$853 million, a decline of 5.6% YoY and a growth of 7.4% on a sequential basis. Strong performance across key
    markets, further aided by favourable forex, was offset by lower Lenalidomide sales. NRT revenues declined primarily due to the change
    in operating model post-integration, under which rebates and discounts are offered to distributors and recognized net of revenues,
    as compared to the transition period when sales were managed by the seller, Haleon. This change in operating model is profit neutral.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated gross profit margin was 46.5%, a decrease
    of 1,039 basis points YoY and an increase of 169 basis points sequentially. The decline in margins during the quarter was largely
    on account of lower lenalidomide sales, the semaglutide API related provision mentioned earlier, as well as higher solvent cost on
    account of the Middle East conflict. The reported gross margin was 51.6% for Global Generics and 4.5% for PSAI. Excluding the semaglutide
    API related provision mentioned earlier, the overall margin was 49.4%, while that for Global Generics was 53.8% and for PSAI was
    12.9%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The SG&amp;A spend was at &#8377;2,882 crores, an increase
    of 12% YoY and 4% sequentially, accounting for 36% of revenues. The YoY increase was primarily driven by higher personnel costs due
    to annual increments, adverse forex movement, targeted investments in the branded businesses, as well as elevated freight costs arising
    from disruptions related to the Middle East crisis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The R&amp;D spend was at &#8377;577 crores, declined
    8% YoY and up 6% sequentially, accounting for 7.1% of revenues and reflecting lower biosimilars development expenditure as compared
    to the previous year.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying EBITDA, including other income, stood
    at &#8377;1,009 crores for the quarter, which is US$107 million, a decrease of 1,416 basis points YoY and 55 basis points sequentially,
    reflecting a margin of 12.5% of the revenues. Excluding the semaglutide API related provision, the margin was at 15.4%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, the profit before tax was at &#8377;553
    crores, that is US$58 million, representing a margin of 6.8%. Excluding the semaglutide API related provision, the margin was at
    9.8%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective tax rate for the quarter was 21.3%, compared
    to 26% in the corresponding period last year. The ETR for the quarter was lower primarily due to reversal of previously recognized
    tax provisions no longer required consequent to the favourable resolution of tax assessment pertaining to the earlier year and a
    favourable jurisdictional mix for the quarter, in comparison to the same period in the previous year.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit after tax attributable to equity holders of
    the parent for the quarter stood at &#8377;443 crores, which is US$47 million, a margin of 5.5% on revenues, before adjusting for
    the semaglutide API related provision mentioned earlier. Diluted EPS for the quarter is &#8377;5.32.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating working capital as of
    30<SUP>th</SUP> June 2026 was &#8377;14,353 crores, which is US$1.52 billion, a decrease of &#8377;81 crores over 31<SUP>st</SUP>
    March 2026. Capex cash outflow for the quarter stood at &#8377;307 crores, which is US$32 million. Cash flow during the quarter before
    acquisition related payout was negative &#8377;216 crores, which is negative US$23 million. As of June 30, 2026, we have a net cash
    surplus of &#8377;3,057 crores, i.e., US$323 million.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency cash flow hedges executed through
    derivative instruments during the period are as follows. US Dollar 354 million hedged using combination of forwards &amp; risk reversal
    options, scheduled to mature by March 2027. These contracts are hedged at a rate of &#8377;92.34 to 94.63 per US dollar. RUB 2.8
    billion hedged at a fixed rate of &#8377;1.26 per Russian Ruble, with maturity falling within the next three months.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With this, I now request Erez to take us through the
    key business highlights..</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you, MVN and good day to all of you. We appreciate
    you joining us today and thank you for your continued interest in our Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We remain consistent in our strategic priorities and
    committed to delivering growth and profitability through disciplined execution, as the operating environment continues to evolve.
    We are focused on strengthening our base businesses and building future growth engines in peptides, biosimilars, consumer health
    and innovation, while pursuing targeted business development initiatives to augment our organic growth efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying base business delivered healthy double-digit
    growth across all key geographies, including North America. The quarter&rsquo;s EBITDA margin was adversely impacted by semaglutide-related
    challenges, including lower sales, provision for rejected batches, loss of production-linked incentives (PLI) and other associated
    costs, as well as the conflict in the Middle East. Excluding these impacts, we estimate that EBITDA margin would have been in the
    high-teens.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are working towards resolving the issue and are
    planning to resume semaglutide commercial supplies by November. Importantly, there is no risk to any patient who has consumed the
    product. Patient safety and product quality remain our highest priorities and will continue to guide us in every decision we make.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We remain confident of a strong second half of the
    fiscal, with the resumption of semaglutide supplies. The strength of our base business, and our ongoing productivity initiatives
    will continue to support double-digit base business growth and steady margin improvement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Let me now walk you through some of the key highlights
    of the quarter.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">We commercialized a few key complex generic products,
    including the anti-cancer drug, bosutinib, a first-to-market launch with a 180-day of generic drug exclusivity for the 400 mg strength
    and nintedanib, used in the treatment of lung diseases in the United States. In Canada, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we were the first company to secure
    approval for and launch semaglutide for the treatment of Type-2 diabetes. We launched oral semaglutide in India, and remain committed
    to building this important metabolic franchise, complemented by nutrition offerings such as Celevida &lsquo;GLP+&rsquo; through our
    collaboration with Nestl&#233;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We continue to make progress on bringing innovation
    to patients in underserved markets through partnerships. Our in-licensed novel therapy, toripalimab, for treatment of nasopharyngeal
    carcinoma, has entered the &#8377;100 crore club in less than two years of launch in India. During the quarter, we partnered with
    Innoviva Specialty Therapeutics to develop and commercialise, XACDURO&reg;, used in treatment of hospital-acquired bacterial pneumonia
    in select markets across South and Central America, the Caribbean, Russia and CIS countries. Through our collaboration with Global
    Antibiotic Research and Development Partnership (GARDP) and our subsidiary, Aurigene Pharmaceutical Services Limited, we achieved
    an important milestone in our access agenda by securing Thai FDA approval for zoliflodacin, a first-in-class treatment for uncomplicated
    gonorrhoea. The approval came just six months after U.S. FDA approval, making Thailand the first LMIC country to approve the product.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the regulatory front, the USFDA completed a Pre-License
    Inspection at our biologics manufacturing facility in Bachupally, Hyderabad in June 2026 and issued a Form 483 with seven observations,
    which we have already responded to well within the stipulated timelines.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commitment to good governance and sustainability
    continues to be recognized globally. During the quarter, we celebrated 25 years of our New York Stock Exchange listing, reinforcing
    our distinction as the first and only Indian pharmaceutical company listed on the exchange as well as our commitment to global best
    practices in governance, compliance, and capital market access. FTSE Russell placed us in the top 1% worldwide, while TIME&ndash;Statista
    ranked us 165<SUP>th </SUP>globally and 5<SUP>th</SUP> among Indian companies among the World&rsquo;s Most Sustainable Companies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Let me take you through the key business highlights
    for the quarter. Please note that all financial figures mentioned are reported in their respective local currencies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our North America Generics business reported revenues
    of US$236 million for the quarter, accounting for 27% of our overall revenues and reflecting a decline of 41% year-on-year and a
    growth of 19% sequentially. The year-on-year decline was primarily on account of lower revenues Lenalidomide. The underlying base
    business delivered double-digit growth, aided by new product launches. During the quarter, we launched six new products in the region,
    including complex generics such as bosutinib and nintedanib and we remain on track to bring more such products to market as we progress
    through the year.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our branded franchises including India, Emerging Markets
    and consumer health business in Nicotine Replacement Therapy or NRT, together account for 52%* of our overall revenues, and remain
    an important source of stable margins for the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Emerging Markets business recorded
    revenues of &#8377;1,833 crores, accounting for 23% of our overall revenues and reflecting a robust growth of 31% year-on-year and
    2% quarter-on-quarter. Growth was driven by new product launches across markets and favourable currency movements. During the quarter,
    we introduced 43 new products across countries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our India business revenues were &#8377;1,718 crores,
    accounting for 21% of our overall revenues and delivering a robust, double-digit, year-on-year growth of 17% and 10% sequentially.
    This performance was primarily driven by the innovation franchise, new launches including acquired brands, price increases, and volume
    growth.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IQVIA June 2026 data highlights our continued outperformance
    of the Indian Pharmaceutical Market (IPM), with moving quarterly total (MQT) growth of 14.6% versus 13.5% for the IPM and moving
    annual total (MAT) growth of 13.5% versus 11.1% for the market. Our IPM Rank stood at 9<SUP>th</SUP> for the quarter and 10<SUP>th
    </SUP>for the year. We launched seven new brands during the quarter, further enhancing our domestic presence.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our European business, which includes NRT, posted revenues
    of &euro;131 million for the quarter, accounting for 18% of our overall revenues. Revenues were broadly in line with the corresponding
    period last year and declined 3% sequentially, on account of price erosion as well as the impact of operating model changes post
    NRT integration explained by MVN, offsetting the contributions from new product launches in generics. During the quarter, we launched
    24 new generic products across markets, further expanding our European product portfolio.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our PSAI business reported revenues of US$91 million,
    accounting for 11% of the overall revenues. Revenues declined 5% year-over-year and 10% sequentially, primarily on account of lower
    API volume uptake. During the quarter, we filed 38 Drug Master Files globally.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We remain focused on strengthening our core business,
    while building the next wave of growth across peptides, biosimilars, consumer health, and innovation. We will continue to advance
    key products such as Semaglutide and Abatacept, improve operational efficiency, and pursue value-accretive business development
    opportunities to drive long-term value creation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With that, I invite your questions as we move into
    the Q&amp;A session.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you very much, Erez. We will now begin the question-and-answer
    session. To join the question queue, please use the &lsquo;raise hand&rsquo; option available on the bar at the bottom of your Zoom
    application. If you wish to exit the question queue, you may click on the &lsquo;lower hand&rsquo; option. Participants are requested
    to not ask more than two questions at a time, and to rejoin the queue in case of any incremental queries. I would like to reiterate
    that the chat will not be monitored for any questions to the management. However, in case of any technical concerns, please do feel
    free to use the chat option to reach out to us.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first question is from the line of Neha Manpuria
    from Bank of America. Neha, please go ahead.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neha Manpuria:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes, my first question was that
    we had given a guidance of 20% margins excluding semaglutide. So, just wanted to get a sense of how we improve the current high teens
    margin that you&rsquo;ve indicated, adjusted for semaglutide and the Middle East impact, given that we&rsquo;re still uncertain about when semaglutide
    comes back and how much it comes back in the second half.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neha, if we are taking out from the 12.5% the impact
    of what we provided, plus what we did not sell, and in addition the PLI and the rest of the staff, what I said, the high teens, it&rsquo;s
    actually around 18%. Okay, so the equivalent of the 19% last quarter, it&rsquo;s 18% for this quarter. Still I maintain what we discussed
    a few weeks ago, that we are in the neighbourhood of the 20% and likely to stay. And that&rsquo;s what we are saying we will do including
    the next quarter, which will not be with semaglutide, so that&rsquo;s still the case to be in the neighbourhood of the 20%. As we will
    resume, with the assumption that we will come back with semaglutide in November, of course, the margins will be higher than that.
    So we are maintaining what we have discussed in June.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neha Manpuria:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood. And, second question is on the US business.
    There seems to be a decline quarter-on-quarter, despite the fact that we launched Canada, we had bosutinib. And I&rsquo;m adjusting the
    shelf stock adjustment in the base quarter here. What exactly happened in the US? Given we had the bosutinib FTF launch, I would
    have assumed some channel filling, as well as the Canada supplies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, nothing happened, it&rsquo;s actually in the right direction.
    It&rsquo;s some timing of procurement of the product and the launch of the product was very successful. So overall, I&rsquo;m still maintaining
    a double-digit growth for the US market. As you saw already in this quarter, we grew double-digit and it will continue throughout
    the year. So it&rsquo;s double-digit growth in the United States. It&rsquo;s just timing of product and nothing special.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neha Manpuria:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you so much.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Neha. The next question is from the line of
    Dr. Kunal Dhamesha from Macquarie. Kunal, go ahead, please.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hi, good evening, thank you for the opportunity. First
    question on abatacept update. So, two aspects here. One on plant inspection, where we have got 7 observations, and we have submitted
    the response. But let&rsquo;s say when we compare the observation, with the last inspection, which had 5 observations, how do those compare?
    And, second aspect. From an ongoing dialogue perspective with the US FDA on the product approval, what are the types of queries we
    are receiving? Is it on data on the clinical side, manufacturing-related, CMC-related? Colour here would be helpful.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Sure. So, the 7 observations were very different, than
    those we got. And we believe that they&rsquo;re addressable. And we sent all the relevant information to the US FDA on Friday, which was
    well within the stipulated time. So we will seek feedback, obviously, from the FDA of what we submitted. As related to the BLA, we
    did not receive any query as we speak. The goal date of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product is still in December
    and this is still intact. We did not have any query or any ask as of date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, and, on that inspection, what is your understanding?
    Would it require another inspection, or the response you have submitted would suffice?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To my opinion, we should get approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure. So, that&rsquo;s the first question. Second question
    is some of the productivity measures that we have talked about in the past, right? That we will try to improve the efficiencies.
    But the way I see it, when I look at the SG&amp;A expense without R&amp;D, QoQ is still higher, right? So, is there any specific
    cost-saving measures we are undertaking? If yes, what&rsquo;s the quantum, in terms of saving that we can see, and when those measures
    would be visible in the overall performance?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, Kunal, we said our absolute SG&amp;A amount will
    be largely in line with FY26 actuals. This quarter, whatever growth you have seen, largely is on account of adverse forex rate movement,
    as well as there&rsquo;s elevated freight cost on account of the Middle East conflict. What increase you have seen on either QoQ or on
    the year over year, almost, 75% to 80% on account of these two factors. Otherwise, if you take it out, then there is not much of
    a significant increase.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, just to comment to your point, we are planning
    to grow in double digits and we are planning to grow the associate costs by low single digit. So, the productivity measures will
    be primarily that the sales that&rsquo;s associated, obviously, with this S&amp;M, will grow much faster than the expenses. 52% now of
    our business is branded markets. So naturally, in such a case, we need S&amp;M to grow the business, and what is important, they
    will grow the sales much faster than the cost. In this case, we are talking about a gap of 10-12%, because between the sales growth
    and the cost growth and that&rsquo;s the productivity you are going to see.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And when should we start this difference in the growth?
    I assume it would be gradual, right, eventually? Or it&rsquo;s just linked to the revenue, and not any specific cost measure?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No, no, it is. First of all, you already see that.
    And I know it&rsquo;s hard because of all those one-time activities or war impact, but you already see it. And as time will go by, obviously,
    we&rsquo;ll see it more. But the way to see it is that eventually the growth is in the Emerging Markets, most of the S&amp;M is in the
    Emerging Markets. And the growth in Emerging Markets is right now north of 15%, and in some places more than 20%, while the cost
    growth is in very low single digits, if we take out the one-time activities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, and last one, if I may just squeeze in. One is
    we have around &#8377;3,000 crores of cash on the balance sheet, right? So what kind of opportunities are we looking at from the
    business development activities? And secondly, on today&rsquo;s announcement from US President on tariffs on generics, as to how we think
    about the overall development? I know the details are missing. But what would be your initial impression of that and how would you
    tackle that? Thank you.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, first of all, we are engaged
    in business development. I also mentioned it in my script. There are actually quite a few deals that we are engaging in all sectors,
    in generics, in innovation, in biosimilars, and hopefully we can announce those deals as we sign it. So the cash and the balance
    sheet will be used for inorganic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the tariff. We&rsquo;ve been there last year. Obviously,
    it&rsquo;s a tweet. And between a Tweet and the reality, a lot of things likely to happen. As we speak, I don&rsquo;t see any reason to be concerned.
    Even according to the Tweet, we are supposed to have two years without tariff. It&rsquo;s not practical to move any facility in two years.
    You know it well, everybody knows it well. So I&rsquo;m assuming that it&rsquo;s an opening for a discussion and dialogue. Both the IPA here
    in India, as well as the association in the United States have already engaged on that. So we will see as it evolves. Personally,
    I don&rsquo;t, at this stage, give it too much weightage.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also if I may add, almost 25-30% of our revenues are
    actually being manufactured by CMOs in the US, so we already have that as a starting point.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, but I will not give too much weight at this stage
    for that. Let&rsquo;s see how it will evolve. We&rsquo;ve been there last year. And, between how we started and how it ends, it was very, very
    different.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Kunal Dhamesha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, thank you, and all the best.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks,
Kunal. The next question is from the line of Tausif Shaikh from BNP Paribas Exane. </FONT>Tausif, please go ahead.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tausif Shaikh:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Aishwarya, for the opportunity. Good evening.
    First few questions on semaglutide pens and API. Can you tell us how many pens has Dr. Reddy&rsquo;s been able to sell during the
    quarter? And a broad breakup regional-wise would be helpful.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, so we sold 180,000 pens before we stopped. We
    were supposed to sell more, by the way, but obviously, that&rsquo;s also part of the reason why there is relatively high level of provision
    that we had to do on material and batches that we could not use. Obviously, most of it will be for the market of Canada. We have
    also for India. We are still maintaining what I said 9 days ago. With the assumption that around the third week of September we are
    supposed to finish all the testing of the API and then supply to our partner, OneSource. We have the slotting and agreement with
    them, and if everything will go well, we should be able to give to the market 6 to 7 million pens between November and March.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tausif Shaikh:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, that&rsquo;s helpful. Second question on the semaglutide
    API. Just wanted to confirm that Dr. Reddy&rsquo;s is also supplying this API to many global pharma manufacturers who are also your competitors
    in Canada and other markets. Just wanted to understand your strategy over here. How much percent of capacity Dr. Reddy plans to keep
    for captive consumption for the future?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No, we have plenty of capacity.
    The theoretical capacity - I&rsquo;m saying theoretical because we need to scale up in the satisfactory manner - can go up to 550, but
    let&rsquo;s say even without the expansion, it can be north of 300 as capacity. We have plenty of capacity for both third parties as well
    as ourselves. At this stage, not relevant, it&rsquo;s more about the quality of the API, not the capacity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tausif Shaikh:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The last question about abatacept, what would be your
    timeline for the launch if the product has to be approved from a CMO? Can we expect some delay from the earlier guidance which we
    have planned in calendar year 2027?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abatacept is not out of a CMO. Abatacept is made by
    our own facility in Bachupally, and that&rsquo;s the facility that underwent the FDA inspection. The timing is, launch upon approval. Right
    now, the goal date is December, so obviously, we hope for that. But we need to see whether we will get additional queries. And if
    not, we&rsquo;ll stay intact.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tausif Shaikh:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">But I guess, we have filed the product from two of
    the facilities, right? The other one is from a CMO. We have done dual filings for the product, right?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abatacept was filed only from our Bachupally site.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tausif Shaikh:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood, that&rsquo;s helpful. I&rsquo;ll get back in the queue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you, Tausif. The next question is from the line
    of Damayanti Kerai from HSBC. Damayanti, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hi, thank you for the opportunity. My question is,
    again, on semaglutide. So, as you continue to work towards resuming supplies after addressing the OOS issues, we understand in some
    of your targeted markets, new players are getting approvals, etc. We understand you are B2B supplier to a few of them, but nonetheless,
    by the time you get back in these markets, how do you assess the competition scenario and your ability to gain market share there?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So we believe right now that the demand for the 6 to
    7 million pens will be there for us. And, it&rsquo;s even backed with orders, so we believe that we&rsquo;ll be able to sell all the 6 to 7.
    Obviously, it&rsquo;s a bummer. We cannot deny it. The consequence is we lost the 4 months of sales. So, obviously, from the 10-11 to the
    6-7, this is the impact on us. But we feel that we will stay there, and that the demand for the product is still very high. And the
    people that will enter the market in these 4 months, to the best of our knowledge, there are not that many, at least in the markets
    that we are planning to get approvals. So, it&rsquo;s a bummer, but we believe that the product will stay solid for us.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and, also wanted to understand, this API issue,
    will it impact the review of application for semaglutide in some of the markets, apart from, obviously, Canada, where you have approved
    product. But, say, in Brazil or in other markets, will the applications be halted till the time you resolve the API issue?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No, because the specifications (specs)
    stay the same. So, we are not changing the specs or the quality. It was just our ability to meet the specs in the scale-up batch
    of the API, which we need to resolve. But, the file is good. And the quality of the drug product is good. So, I don&rsquo;t anticipate
    any delays or a change to our applications anywhere, including Brazil.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, so in how many countries you have filed a semaglutide
    application so far?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More than 20, 30 countries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oh, for sure. So, the program of the 80 countries remains
    the same. If I remember correctly, but please forgive me if I&rsquo;m not fully accurate is around 30 countries already.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, and my last question is, how should we look at
    R&amp;D and tax rate from here on? So, we understand this quarter had some benefit on the taxes, but on a normalized basis, how should
    we look for the full year?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, our tax rate is around 24% to 25% on the full year
    basis and R&amp;D, what we have stated earlier, it is in the range of 7% to 8%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and any major R&amp;D programs, after abatacept,
    where you plan to spend majority?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So we have a long pipeline for the future, both on
    the peptides, as well as additional biosimilars. This year that it will be closer to the 7%, like MVN said, but most of the R&amp;D
    spend is right now going to products post-2034, between 2034 to 2040 type of products. That&rsquo;s where the R&amp;D goes. Besides, of
    course, some allocation that comes for licensing fee, as well as remediation of products. But mostly, it&rsquo;s for later products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Damayanti Kerai:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, thank you. I&rsquo;ll get back in the queue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you, Damayanti. The next question is from the
    line of Saion Mukherjee from Nomura. Saion, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, thanks for taking my question. Since you last
    addressed on the semaglutide situation, is there any progress in terms of root cause analysis, and how you see possibility of a resolution?
    How do you assess the risk of that program at this stage?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So we identified the root cause. We started, also,
    the activities in the site. There is a program management that takes us, again, to around September 22<SUP>nd</SUP>, September 23<SUP>rd</SUP>.
    The success rate is high, I don&rsquo;t know exactly the percentage. If I need to throw a number, it&rsquo;s somewhere between 80% to 90%. But
    there is a chance that it will fail, I just want to make sure, it&rsquo;s not 100%, but we feel relatively confident. Let&rsquo;s cross our fingers
    on that.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I see, okay. And just one last one on CAPEX. What&rsquo;s
    the guidance for this year on CAPEX and for next year, please?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This year, I think around &#8377;1,800
    crores on the full-year basis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And will this come down next year, you think?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hopefully, that&rsquo;s what is our expectation, but around
    that range, because, there&rsquo;s continuous specific product investments in biosimilars and peptides, and then a regular CAPEX, Saion.
    But already, if you see, earlier, we were in that &#8377;2,500 to 2,700 crores range, and from there, we have just this year, reduced
    to &#8377;1800 crores. I believe that it will stay at that level.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, sir, if I can just ask one question, because
    you mentioned about Middle East conflict and freight cost, etc. What&rsquo;s the level of impact, either as a percentage of sale or in
    absolute amount, if you can quantify?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both solvents and the fright on the EBITDA is close
    to around 1%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and is there any improvement now? Because the
    conflict seems to have escalated once again, so how you see for the rest of the year?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, as long as it continues. Earlier we thought, suppose
    it stops, then all the solvent prices will decline. And now, because, once again, the war is going on, I think, this level of increase
    will stay at least up till December.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I see. Okay, thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Saion. The next question is from the line of
    Rahul Jeewani from IIFL. Rahul, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rahul Jeewani:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, thank you, sir, for taking my question. I wanted
    some clarity in terms of our base business growth. Now, if I look at our North America revenue base, in FY22, it was close to a billion
    dollars. And if I take this quarter&rsquo;s number, then we are annualizing at around US$950 million. Now, over these past 4 years, we
    have launched around 90 to 100 products in US. We did a Mayne acquisition as well, which contributed US$100 million in terms of incremental
    revenue. So, despite these launches and Mayne acquisition, where have we struggled in terms of driving growth on the base US business?
    So, if you can please comment on that.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Obviously, we faced on the base of the FY22, or any
    other year that you&rsquo;re referring, a significant price erosion that was through this period of time. In some of the years, it was
    even in double digits. In some of them, it was in single digits. This is, and you know that very well, very normal for the United
    States. And against that we brought new products, some brought more value and some less. Overall, I&rsquo;m reiterating what I&rsquo;m saying
    all along, that the US market, the generic piece of it, is at best single-digit growth, without the upsides. And from time to time,
    there is an upside that comes, we had upside through the years, whether it was lenalidomide, and before that there was other products.
    So, that piece of the market is a single-digit growth, even low single-digit type of a market, in which new products compensate for
    price erosion. The reason <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that we are still there, is that
    this group of products is what&rsquo;s feeding the growth in Emerging Markets, as well as in Europe, so the leveraged growth. And what
    you see now in Europe, as well as in the Emerging Markets, is primarily the US portfolio that is growing there. So we moved from
    investing in the US to take a product and launch it globally. And, so overall, the ROI of the product that we launch in the years
    that you mentioned actually gave us a very, very good ROI. Just it&rsquo;s not coming in the United States. We see it in the other markets.
    In addition to that, we&rsquo;re obviously diversifying ourselves to other business models, as we stated. But to your analysis, you are
    correct. In this period of time, if you take out product like lenalidomide, your analysis is correct.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rahul Jeewani:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, sir, and do you think that we have lagged peers
    in terms of R&amp;D productivity for the US generic business? Given that many of our Indian peers have been able to launch products
    in, let&rsquo;s say, a respiratory segment or injectables, which has allowed them to scale up their US portfolio while we, obviously, seem
    to have had pretty muted performance on the US business over the past 4-5 year period. So, is there any issues in terms of the productivity
    for our R&amp;D business, and do we have any measures in terms of evaluating this R&amp;D productivity, particularly for the US generics
    business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, to your question, yes, we failed in certain complex
    generics. We even stated some of them in the past, like iron sucrose, conjugated estrogen, some of the peptides that we were late,
    so the answer is yes. We did have these issues. I believe that, we corrected it. Obviously, as we know very well, the R&amp;D expenses
    of today is for products that we will launch, on an average, 10 to 12 years from now. So, obviously, the products that we launched
    in this period of time were products that were developed before that. And we absolutely had productivity issues, and I believe that
    we took the right measures to correct it. And again, I agree with your observation. I believe that we took care of it.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rahul Jeewani:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, sir, and last question from my end. On abatacept,
    I was also under the impression that we would file abatacept from the partner facility as well, but right now you&rsquo;re saying that
    abatacept is only filed from Bachupally. So, do you see any risk to abatacept now in terms of, let&rsquo;s say, contributing to us in FY28,
    and are we evaluating an alternate site filing for abatacept?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">So
    abatacept was never meant to be filed from a CMO. It was developed and meant to be filed out of Bachupally from our CCM5, which is
    our drug substance, and our FFM2, which is the fill-in-finish, both of them in Bachupally. So that was always the plan. There was
    some discussion in the past whether, because of tariffs, we should get a CMO in the United States. We did engage with this issue,
    but tariff became not relevant. Plus any CMO that we will do now will have to be a post-approval supplement, because first they will
    have to approve the product, and then, based on that, you can add the information about the CMO. So any activity like that will be a
    post-approval supplement, and will require also relatively high cost, because, as you know, CMO of a biologics product is not cheap.
    At the moment, the launch will be out of Bachupally. About the risk, there are two types of risk. One is in the case that we will
    have additional queries on the GMP, and I believe that it&rsquo;s addressable, like I mentioned, but it is possible to get. And second,
    queries that we may get on the BLA. If we will get this, naturally, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">can delay the launch of abatacept.
    As we speak today, the goal date for abatacept is in mid-December 2026.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rahul Jeewani:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, sir, that&rsquo;s it from my side. Thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Rahul. The next question is from the line of
    Vivek Agrawal from Citi. Vivek, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vivek Agrawal:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Aishwarya. Thanks for the opportunity. Just
    want to understand, the India business has done a good growth in the quarter. So, just want to understand what is organic growth,
    if we remove a couple of small acquisitions that made. Thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In India, if we remove the different acquisitions,
    it&rsquo;s 15%?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5%, fully organic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vivek Agrawal:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood. And does that include semaglutide supply
    as well?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not much, Vivek.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vivek Agrawal:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood, thank you. Just one more question on bosutinib.
    So, does this include a full quarter impact of launch, or it&rsquo;s just a very small launch in this quarter?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s one month.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than a month, actually. It&rsquo;s two weeks.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its two weeks of supply and we have exclusivity on
    the 400 mg.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vivek Agrawal:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood. Thanks, that&rsquo;s from my side. Thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Vivek. The next question is from the line of
    Dr. Bino Pathiparampil from Elara Capital. Bino, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Bino Pathiparampil:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hi, good evening. Just a couple of quick questions.
    One, in Canada, I believe we had an arrangement to provide semaglutide to Sandoz as well. Does that deal still hold, and are they
    going to wait for our supplies to be back?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, it still holds, and we believe that if supply
    will come back in in November, we&rsquo;ll be able to meet the commitment to Sandoz.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Bino Pathiparampil:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it. And, second on bosutinib.
    I believe it&rsquo;s a partnered product. You are selling it in the market. What would be the broad profit share arrangement? Is it equal
    or do you make only a distribution margin?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, overall, margin from this product is above company
    average margin.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Bino Pathiparampil:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it. Thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Bino. The next question is from the line of
    Surya Patra, from PhillipCapital. Surya, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surya Patra:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, thanks for the opportunity. My first question
    is about NRT. You mentioned in your opening remark that we have seen a decline this quarter. This is after the complete integration
    of the acquisition. So, can you give some sense of what led to this kind of decline, and whether this is a kind of a trend likely
    to be seen even in subsequent quarters?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No, the trend is a trend of growth. What we had this
    quarter is that in some markets, because of the cutoff in inventory that were in the market, we did not sell in some weeks in this
    quarter. Plus the timing of the tender in Brazil, which we won but we did not sell in this quarter. So, overall, you should see continual
    growth and very, very healthy margin. So far, so good on this one.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, apart from what Erez said, Surya, there is another
    one. Till March 2026, last year, we were just dependant on Haleon and we were paying a certain fee. And this year, we completed the
    integration by March 2026. The entire sales we are operating as part of this new model. What Haleon was offering earlier, rebates
    and discounts, were not impacting the sales line. But this year, now, since we are directly distributing the product to the customers,
    the rebate and discounts we are giving is now part of the gross-to-net in the revenue line. Correspondingly, there is a SG&amp;A
    reduction. Overall, if you look at the profit, it is neutral, absolutely, there&rsquo;s no impact. Overall of this business, EBITDA margin
    is very healthy, and the business momentum is continuing in the very right direction.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All right, thanks. Thanks, Surya. The next question
    is from the line of Shashank Krishnakumar, from Emkay Global. Shashank, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shashank Krishnakumar:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, hi, thanks for taking my question. My first one
    was on our rituximab filing. I think one of our competitors has received interchangeability status recently. So does our filing also
    include comparative data, so that on approval, would we also get interchangeability on this product?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, so, rituximab, for sure, will be interchangeable.
    As you know, rituximab approval in the United States got delayed. So for us, it&rsquo;s mostly to obtain approvals, because the USFDA inspection,
    PLI, was for both abatacept and rituximab. Once we get, our partners will not have a problem to switch products. So, our products
    will be also interchangeable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shashank Krishnakumar:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it, thank you. That&rsquo;s helpful.
    And second one on denosumab. I think, obviously, our filing was stuck because of issues at our partner&rsquo;s facility. I believe our
    partner has addressed the FDA&rsquo;s observations, but the resubmission obviously has to happen at our end. So, have we resubmitted the
    BLA for denosumab?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BLA is coming only from our partner. It is also
    making the products in that site, and we are now in discussions with the partner on what to do with this product.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shashank Krishnakumar:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it. Thank you. That&rsquo;s it from my side.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Shashank. Participants are requested to restrict
    the number of questions to just one to ensure that everyone on the call gets an opportunity to interact with management. The next
    question is from the line of Yogesh Soni, Haitong Securities. Yogesh, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yogesh Soni:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks for the opportunity. So my question is with
    regards to the semaglutide API provision that you have taken. If you could help us understand, had this provision not been taken,
    what would have been the pen volume that would have been sold? So the question is coming to understand what is the opportunity lost
    that we have faced, as a result of this API provision.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, the opportunity is about 3 to 4 million pens, assuming
    that we are coming back in November.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yogesh Soni:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood. And, thank you for that. And second question
    is, in one and a half months of commercialization in this Canada market, what kind of market share did we enjoy in the semaglutide
    space?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, so we did not have the chance to sell much, so
    I cannot really speak on market share. Obviously, we were one of the first to launch, along with Apotex. So, naturally, by the time
    that we&rsquo;ll come back, it will probably be going to be only the two of us. So, naturally, one year or two, it&rsquo;s a relatively high
    market share, but we did not manage to get market share, per se, as we did not sell much.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yogesh Soni:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If I can, squeeze in one more question. So, given that
    we are looking to resume the supplies from November, what gives us the confidence of doing around 6 to 7 million pens, given that
    Apotex would have already scaled up its market share in the next 3 to 4 months. So how difficult does this target seem to us?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, the confidence is high. It&rsquo;s not just Canada for
    us. By that period of time, we&rsquo;ll have approval in quite a few markets, plus we have engagement with partners. We mentioned some
    of the names. So, the confidence is very high. Actually, all of our partners are looking forward that we&rsquo;ll come back. So, like I
    mentioned before, I believe that we will have a solid demand for these 6 to 7 million pens. And also, I believe that our relationship
    with our partners will allow to make this product, as required. We just need to give them the API.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yogesh Soni:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you, Erez, for your clarifications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Yogesh. I would once again
    request everyone to restrict the number of questions to just one, since we have many in the question queue. The next question is
    from the line of Amlan Jyoti Das from JP Morgan. Amlan, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amlan Jyoti Das:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, so my question is regarding the Canada market.
    So we have seen that a third competitor has also got approval recently, and one of the other competitors are targeting a December
    end approval. So, with 3 to 4 players in the market, what kind of pricing do you see in the Canada market when supply resumes for
    you in November?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, the partner that got approval is using our products.
    So I&rsquo;m not anticipating any more prices, because the price went Day 1 to the type of market that reflect the three players and above.
    So I do not anticipate additional pricing or reimbursement pricing. And naturally, once we&rsquo;ll come back and we&rsquo;ll see how many more,
    we may have to change rebates or stuff like that, this is yet to be seen. But at the moment, also, the one that got approval is waiting
    for us to resolve the operation issues.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amlan Jyoti Das:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, just to put in perspective, what kind of prices
    do you expect then? So, would it be in the range of $30, say, or would it be lower than that? Could you just give us a directional
    sense on that?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As you know, and I discussed it in previous meetings,
    the price in Canada is CAD 78. And then from that, you need to have the margins that you need to give to the relevant retailers,
    depends on the type of market, whether it is a private market, public market, or cash market. So, range is from 38%, which is for
    the retail, and for what you call the private market. And then depending on how many patients are also reimbursed by the relevant
    provinces, you may need to give additional 5% to 6% to the relevant province. That did not change from our previous meetings. It&rsquo;s
    the same set of numbers.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amlan Jyoti Das:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank you. My next question is regarding the US. So,
    you had guided for double-digit growth in the US. So is the guidance for the base business, excluding semaglutide. Just wanted a
    clarification on that.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, semaglutide is in Canada. So we are not selling
    in the United States. So yeah, it&rsquo;s without semaglutide, and without lenalidomide.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amlan Jyoti Das:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, ex lenalidomide, which primarily from the US, it
    will be double-digit growth.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s a double-digit growth and was already there this
    quarter.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amlan Jyoti Das:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perfect, thanks.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Amlan. The next question is from the line of
    Sumit Gupta from Antique Stockbroking. Sumit, please go ahead.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sumit Gupta:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hey, hi, thanks for the opportunity.
    Sir, what are the biologics sales globally as of now, and when can we expect it to break even?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s about 2% of the overall.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s about 2% of our sales, and we are supposed to
    be profitable the day that we launch abatacept.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sumit Gupta:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay. And how should we see abatacept going forward,
    let&rsquo;s say, over the next 2 to 3 years? So, what is the timeline you expect?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So we submitted the IV products in the United States.
    Like I mentioned before, December is the goal date. That&rsquo;s the earliest we can get approval. We can launch upon approval. The Europe
    IV was also filed, but it&rsquo;s very, very small, because in Europe, it&rsquo;s primarily the subcutaneous. In terms of the subcutaneous, it
    will be in 2028, likely around March of 28, or February &rsquo;28 in the United States, and probably around September to October
    in Europe.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sumit Gupta:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Understood, sir. Thank you.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks, Sumit. The next question is from the line of
    Vishal Manchanda from Systematix. Vishal, I would request you to restrict yourself to just one question, please.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vishal Manchanda:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hi, thanks for the opportunity. On our biologics plant
    inspection, can you share whether we had any observations related to sterility assurance?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No, not as such, and like I mentioned before, all the
    observations are addressable, and we already answered them.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vishal Manchanda:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And do you expect any scale-up issues in abatacept,
    like we saw in semaglutide?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s obviously very, very different product. I hope
    not. We are not planning that. But, you know, in pharmaceutical, you never know. But right now, we are optimistic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vishal Manchanda:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it. And PLI incentives, if you can call out, do
    we expect any meaningful number here?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, in the first quarter financials, no PLI.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vishal Manchanda:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anything in the next 9 months? Meaningful?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, as per PLI scheme also, we should have, for the
    set of products, minimum growth. Once semaglutide supply resumes, we will assess, and then if the growth is there, and then PLI,
    we start accounting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vishal Manchanda:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Got it. Thank you.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The next question is from the line
    of Krishnendu Saha from Quantum Mutual Funds. Krishnendu, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, just quickly, we are supplying to partners with
    Sandoz, Aspen, and others. Is there any penalty we have to pay for failure to supply?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, here, as per the orders we received from India,
    like, Torrent and USV and whatever is as per the agreement, that&rsquo;s already taken care of. And in case of Sandoz, Aspen, at this point
    of time, we don&rsquo;t expect any such claims.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and just to jog my memory, the API is being supplied
    from a USFDA plant, or which plant is it coming from?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is from our Vizag plant CTO-6, USFDA-approved
    plant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, if there&rsquo;s an OAI from this plant, does our approval
    in Canada get a setback?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There&rsquo;s no OAI. If there will be an OAI, then it will
    affect the US, maybe the Canadian will do that? But it&rsquo;s very hypothetical, because the US inspected the plant already this year,
    and we got approval. So, not relevant. But that&rsquo;s a hypothetical question. Canadian and American are different regimes.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and this 400 mg for which we have exclusivity,
    how big is the market size, just for my knowledge, please?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bosutinib is about $300 million as far as the market
    concerned.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And how&rsquo;s the nicotine patch doing for us as of now?
    Any growth rates you&rsquo;re seeing out there? Is it a profitable business for us?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It&rsquo;s
    profitable, it is growing, and we are very happy with it. We answered these questions before.</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guys,
    if we can, not repeat questions. We&rsquo;re happy to give our time, but please.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Krishnendu Saha:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sure, thank you, thank you very much.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The next question is from the line of Rupesh Tatiya
    from Longequity Partners. Rupesh, please go ahead.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rupesh Tatiya:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, my question is on interchangeability in Canadian
    markets. So, there are these various provinces which gives out interchangeability designation, and also, I think private insurers
    also give interchangeability designation. And most of this insurance has a clause of mandatory generic substitutions. So, so could
    you give colour on what does it take to get this interchangeability designation, and when that happens, my expectation is all of
    the prescription volume will move to generics. So, when do we expect that to happen? So any colour on that will be helpful. And the other aspect
    also is the innovator&rsquo;s product is recombinant product, and our product is synthetic product, so does that create some problems for
    this interchangeability tag?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So there is no problem with interchangeability in any
    market. The product is approved as generic and the type of the API doesn&rsquo;t affect it. So the semaglutide is approved as a generic
    product. No issues of interchangeability, and you don&rsquo;t need to prove anything beyond what the normal submissions. We had to show,
    obviously, comparability, as well as all the relevant safety, like immunogenicity and other data.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rupesh Tatiya:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So next year, then, generics will have 80-90% market
    share in Canada. Is that a fair thing to assume?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I don&rsquo;t know about that. It&rsquo;s about also the confidence
    of the people. At least at the launch time, the allocation of the retailers assume 60%, and then will grow.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rupesh Tatiya:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pardon for interruption. Insurance-driven market. I&rsquo;m
    not asking about out-of-pocket or retail.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I&rsquo;m trying to answer that. It started with 60%, and
    likely to go higher. What exactly the number will be, I don&rsquo;t know, but yeah, I believe that as the confidence and the supply will
    be there, it&rsquo;s going to be primarily generic market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rupesh Tatiya:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, and then just quickly, when do we expect Brazil
    approval for us, or any of our partners? Any time estimate you can give?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It should be shortly. All the stuff about the rejection
    was reversed and we are expecting approval in the next few weeks.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rupesh Tatiya:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, thank you. Thank you for answering my questions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the interest of time, we&rsquo;ll take one last question
    from Saion Mukherjee. I think he&rsquo;s joined back the queue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, thanks for taking the follow-up. Just a couple
    of questions. So, in the US, I think you mentioned 20-25 launches. How many we are expecting through the rest of the year, and are
    there any material launches, that are lined up, or you expect?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, altogether, right now, we are targeting 27. And,
    at least, we are supposed to have a reasonable launch, let&rsquo;s call it, I cannot share the name of the product, already in the next
    couple of weeks. So, in the second quarter.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">And how large is the opportunity? Can you give an idea
    about the size or the revenue potential from that launch?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erez Israeli:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It should be in the range of tens of millions of dollars,
    that specific launch.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="rdy0931_ex99-1img01.jpg" ALT=""></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Q1FY27
                         Earnings Conference Call Transcript</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>July
22, 2026</I></FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay, thank you. And MVN, I understand
    biologics and peptide facility operations are not generating any revenues at this point. What&rsquo;s the revenue-cost mismatch there?
    What&rsquo;s the cost that is hitting the P&amp;L on account of this, which is not generating any revenues?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So, in the biologics, already we invested in CCM-5
    for abatacept. We are just waiting for approval, and then whatever are the expenses is already hitting our P&amp;L. Similarly, we
    have created the capacities for peptides, both for API and formulation. So fill-finish also is there. Once these two products come,
    and definitely, then it will be profit positive.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeah, but I was wondering if you can quantify the amount
    of cost that you&rsquo;re incurring on account of these two at this point.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. V. Narasimham:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I&rsquo;ll just come back.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Saion Mukherjee:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Okay.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aishwarya Sitharam:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That was the last question. Thanks, Saion. Thank you,
    everyone, for joining us today. We value your time and your participation on this call. If you have any further questions, or need
    any additional information, please do feel free to reach out to me. With that, we conclude today&rsquo;s earnings call. Thank you very
    much.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*Note:
The contents of this transcript have been edited for accuracy and readability, without altering the substance of the discussion.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>rdy0931_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rdy0931_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y -(# 2(  A$! Q$!_\0
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MJ7$.<Y)2JU*^7RHTWSY70@JM64)P<9*HG"M:+C)3?*E*$K'K8CA^2H5Z\7_
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MO"_CGP?XG$D=_P",O /@_1M=T*ZL=.M;JTU?PQXGGGFC:2V@L(Y;5+IOK/\
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M&OV1/VQ?B/XA^,D6L>,?@E\4/%&JW&K^,=5^&YT*X\,>,M5N)9EDU[Q%X/\
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C+1DUJIC&%.5'0[MV>!WR>.V.V.!C%.HH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>rdy0931_ex99-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rdy0931_ex99-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !) / # 2(  A$! Q$!_\0
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MX?5.:4I8>FZE*'M(8NK.E>G_ ."@?[3/@+Q%^Q#\5OBY\-?@M9?LN_MY^/?
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M0HLAF<*'VHAX9L$@\8(K\Y?^"FGP^\?_ !H_8E\0?#CX;_\ "R/^$ZN/C_\
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M7A$'FPR37"?8[)%CCG\MY)OY8?@K\%?BY^SW\(_V?/'&F_L7^-?B/XC^*O\
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MW!USPG\)O!OC^X\'>'Y-+FFFFUO6].T+3;^YN([=]1<J37K7_!,[2_$GAO\
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MNZ%I%UKME;_%36[/Q/X;\065SI>G^$KV6XM+?YV\._\ !5#]N_3OV$/V:_\
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MTD?AKQ))>1VE?C/^WQ^VA\=/VFO^"5?_  6.\&_&KX>_#CP'XS_9D^.'A_\
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MX*+_ +)W[9W@#XES?"/X@6O@O3O@7X N_P!D[QWXCU?XC?%B;PK-X+\ >/\
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M N?^"AOA6^\(?"?4_AG^S[^T#\:/&_Q0\;_%[X8R_ #P4_[/7AOXJ?#?QO\
M :XU33_C-X=^)-W\:?VBOA?\*;%_ASK.BW'AW4)/#GQ&\76FO7T^GZEX'O\
M7?">H66KR?$WPU_8=_:E^$7[-'[ ?C'6/&OQM_:?^*W[('Q ^&WQ3U;]FSQK
MJ/[(V@ZCX;L;;X"?%WX%^/OAW\$/$W@?P%\ O!VJ>+M/L_BW_;FA:K\??BGX
MB@OE\*KH[>-?#4_B+5M1J'Q-^R9\5H?AF_B;Q)^R]^U9K_[0_P 1OC)^U+\;
M/ 6M_LO_ +87AK]GJ/\ 95N/CGXCT";PSX/^,'BC2?VJ?@[IOCW1K/PM\/\
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M=IR S$L0"$3(!. Q4,0,MEB33Z**%3BFW[VK;UDWNV^MWUTU>EE?1""BBBM
#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
